Table 1. Summary of demographic data from initial pilot studies.
| Study | n | Age | BMI | M/F | Avg KL grade | VAS | WOMAC | KOOS a | Embolic agent |
|---|---|---|---|---|---|---|---|---|---|
| Okuno et al 6 | 72 | 64.4 | 25.1 | 23/49 | ∼ 2.0 | 72.0 | 42.5 | NA | IPM/CS, Embozene |
| Bagla et al 11 | 20 | 59.4 | 35.0 | 9/11 | 2.4 | 76.0 | 61.0 | NA | Embozene |
| Lee et al 7 | 45 | 67.1 | 24.9 | 17/54 | 2.7 | 5.6 a | NA | NA | IPM/CS |
| Landers et al 14 | 10 | 62.2 | 31.0 | 4/4 | ∼ 1.5 | NA | NA | 45.0 | PVM, Embozene |
| Little et al 15 | 38 | 60.0 | 30.0 | 18/20 | 2.4 | 60.0 | NA | 54.0 | Embosphere |
Abbreviations: BMI, body mass index; IPM/CS, imipenem/cilastatin sodium; KOOS, Knee injury and Osteoarthritis Outcome Score; M/F, male/female; PVM; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
a
Knee injury and Osteoarthritis Outcome Score.